A Randomized, Open-label, Phase 3 Study of Adjuvant Sacituzumab Govitecan and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy

16760GS-US-595-6184-NCT05633654OpenA Randomized, Open-label, Phase 3 Study of Adjuvant Sacituzumab Govitecan and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant TherapyGS-US-595-6184NCT05633654IndustrialAdultTreatmentIIIOtherMainor, CandaceGeorgetown University Medical Center; Lombardi Comprehensive Cancer CenterBreastOncology GroupLombardi Comprehensive Cancer Center (LCCC)2026.1.0 Build 16 <a href="https://advarra.com" target="_blank">© 2026 Advarra, Inc.</a>